Fast track clinical development for treatments for cancer

Jan Steiner

DOI:https://doi.org/10.5912/jcb430

Abstract:

Comments on the fast track guidance from the U.S. Food and Drug Administration on the treatment of cancer, as of January 2002. Significance of fast track applications to the treatment of cancer; Details of the guidance; Factors that contribute to the fast track approval of a drug; Pros and cons of the fast track development.

Keywords:en ,